Vanguard Capital Management’s Xilio Therapeutics XLO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.79M Buy
198,181
+19,664
+11% +$178K ﹤0.01% 3395
2026
Q2
$1.71M Buy
178,517
+54,857
+44% +$458K ﹤0.01% 3467
2026
Q1
$1.04M Buy
+123,660
New +$1.01M ﹤0.01% 3543

Other funds holding XLO

Vanguard Capital Management's XLO Position: Q3 2026 in Review

Vanguard Capital Management increased its Xilio Therapeutics (XLO) stake by 11% in Q3 2026, buying an estimated $178K and bringing the position to 198,181 shares worth $1.79M. The position accounts for ﹤0.01% of the portfolio, ranked #3395.

Vanguard Capital Management first reported a position in XLO in Q1 2026 and has held it in 3 quarters since. 30 funds tracked by Wall St. Rank hold XLO as of Q3 2026.

  • Vanguard Capital Management held 198,181 shares of Xilio Therapeutics worth $1.79M as of Q3 2026.
  • Vanguard Capital Management bought 19,664 Xilio Therapeutics shares in Q3 2026, an estimated $178K.
  • Xilio Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3395 holding.
  • Vanguard Capital Management first reported a position in Xilio Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 30 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.